伴刀豆球蛋白A
Concanavalin A 可与琼脂糖偶联成 Concanavalin A (agarose) (HY-P2149A)。Concanavalin A (ConA) 是一种靶向葡萄糖和甘露糖特异性碳水化合物结构的选择性竞争性结合剂，可诱导有丝分裂，具有一定细胞毒性、肝毒性及致畸性。Concanavalin A 还应用于糖尿病体内血糖监测。
伴刀豆球蛋白A (琼脂糖)
Concanavalin A (agarose) 由与琼脂糖偶联的 Concanavalin A (HY-P2149) 组成。Concanavalin A (ConA) 是一种靶向葡萄糖和甘露糖特异性碳水化合物结构的选择性竞争性结合剂，可诱导有丝分裂，具有一定细胞毒性、肝毒性及致畸性。Concanavalin A (agarose) 可应用于糖尿病体内血糖监测，从复杂样本中“钓出” 特定的糖蛋白或者去除糖杂质。
Roridin E 是一种葡萄糖-6-磷酸酶 (G6Pase) 抑制剂和抗生素，是 Roridin A (HY-N9599) 的代谢副产物。Roridin E 会引发显著的氧化应激反应，表现为消耗体内谷胱甘肽、诱导肝脏脂质过氧化以及抑制肾脏超氧化物歧化酶活性。Roridin E 能够降低大鼠血糖水平，但具有急性毒性 (与亚油酸 (HY-N0729) 联用时毒性增强)，并会导致雄性白化小鼠出现肝毒性。Roridin E 可诱导血液总蛋白降低以及总脂质、γ-谷氨酰转移酶、碱性磷酸酶和 5'-核苷酸酶水平升高。Roridin E 能够从霉菌中分离得到，具有与 Verrucarin A (HY-107426) 和 Roridin A 相似的细胞抑制和真菌抑制活性。Roridin E 在啮齿类动物中具有体内活性，常被用于肝毒性相关研究。
Cholesterol hemisuccinate (Cholesterol hydrogen succinate) Tris salt 是一种具有保肝和抗癌活性的化合物。Cholesterol hemisuccinate Tris salt 抑制对乙酰氨基酚 (AAP) (HY-66005) 的肝毒性，并防止 AAP 诱导的肝细胞凋亡 (apoptosis) 和坏死 (necrosis)。Cholesterol hemisuccinate Tris salt 抑制 DNA 聚合酶 (DNA polymerase) 和 DNA 拓扑异构酶 (DNA topoisomerase)，从而抑制 DNA 复制和修复以及细胞分裂。Cholesterol hemisuccinate Tris salt 抑制肿瘤生长。Cholesterol hemisuccinate Tris salt 可用于配制缓冲液。
Vitamin U (S-Methylmethionine sulfonium) chloride是一种具有抗氧化活性的口服抗溃疡剂。Vitamin U chloride 抑制脂肪细胞分化。Vitamin U chloride 可促进皮肤伤口愈合。Vitamin U chloride 可用于胃肠道溃疡的研究。
赭曲霉毒素 A
Ochratoxin A 是一种可穿透血脑屏障的食源性真菌毒素，是曲霉属 (Aspergillus) 和青霉属 (Penicillium) 真菌的次生代谢产物，属于 2B 类致癌物。Ochratoxin A 诱导氧化应激、抑制线粒体呼吸、造成氧化性 DNA 损伤、破坏 PPAR-γ-CD36 轴、诱导免疫抑制、介导线粒体依赖性凋亡 (apoptosis)、抑制谷氨酸吸收、引发脱髓鞘病变与神经炎症、导致 DNA 低甲基化及抑制细胞增殖等途径。Ochratoxin A 可诱发肾毒性、肝毒性、免疫毒性、神经毒性，还具有致突变性、致畸性与致癌性。
Icariside I (GH01) 是一种具有口服活性的 Icarlin 代谢产物。Icariside I 通过同时调节成骨细胞和破骨细胞分化改善雌激素缺乏引起的骨质疏松症。Icariside I 促进 ATP (HY-B2176) 或 Nigericin (HY-127019) 诱导的 mtROS 产生以及 NLRP3 炎症小体激活并引起特异质肝毒性。Icariside I 不会改变 NLRC4 和 AIM2 炎性小体的激活。Icariside I 通过靶向 IL-6/STAT3 通路抑制乳腺癌的增殖、凋亡 (apoptosis)、侵袭和转移。Icariside I 是犬尿氨酸-AhR 通路抑制剂，通过阻断肿瘤免疫逃逸来缓解癌症。
朝藿定C
Epmedin C (Epimedin-C; Baohuoside-VI) 是一种口服有效的抗炎剂和免疫调节剂，够靶向结合 UCP1、Caspase-1、CDK2 及 Keap1 等多种关键蛋白。Epmedin C 通过破坏 CDK2/Cyclin E 的复合物功能、抑制上皮细胞增殖。Epmedin C 同时上调 Nrf2 表达、降低活性氧水平并抑制促炎因子分泌，从而有效恢复抗体生成并缓解组织损伤。Epmedin C 具有良好的安全性，且无肝毒性或皮肤致敏性，Epmedin C 已用于肥胖症、Deoxynivalenol (HY-N6684) 诱导的免疫毒性以及乳腺增生等疾病研究。
Icariside I (Standard) 是 Icariside I (HY-N1939) 的分析标准品。本产品用于研究及分析应用。Icariside I (GH01) 是一种具有口服活性的 Icarlin 代谢产物。Icariside I 通过同时调节成骨细胞和破骨细胞分化改善雌激素缺乏引起的骨质疏松症。Icariside I 促进 ATP (HY-B2176) 或 Nigericin (HY-127019) 诱导的 mtROS 产生以及 NLRP3 炎症小体激活并引起特异质肝毒性。Icariside I 不会改变 NLRC4 和 AIM2 炎性小体的激活。Icariside I 通过靶向 IL-6/STAT3 通路抑制乳腺癌的增殖、凋亡 (apoptosis)、侵袭和转移。Icariside I 是犬尿氨酸-AhR 通路抑制剂，通过阻断肿瘤免疫逃逸来缓解癌症。
Sapindoside B 是一种具有保肝活性的物质，同时也是细胞色素 P-450 (cytochrome P-450) 抑制剂、抗菌剂以及膜破坏剂。Sapindoside B 可可逆性抑制肝微粒体细胞色素 P-450 含量，抑制苯巴比妥诱导的酶含量升高，减少细胞色素 P-450 介导的活性代谢产物生成，并减轻肝毒性损伤。Sapindoside B 与 Cutibacterium acnes 脂肪酶结合，降低脂肪酶活性，抑制生物膜形成，减少细菌 (bacterial) 黏附。Sapindoside B 对人癌、肝癌、白血病和胶质母细胞瘤细胞具有细胞毒性。Sapindoside B 可抑制植物病原真菌 (fungal) 的菌丝生长，对皮肤癣菌具有抗菌活性，还具有溶血/溶膜活性。Sapindoside B 可用于肝损伤、Cutibacterium acnes 生物膜相关感染、胃癌、肝癌、早幼粒细胞白血病、胶质母细胞瘤、苹果黑星病以及葡萄灰霉病的相关研究。
DILI 已被证实是一个由多种机制参与的复杂病理过程，其中包括肝脏的结构和功能完整性的直接损害（例如线粒体功能障碍）；产生改变肝细胞结构和功能的代谢产物；产生能与肝蛋白结合的反应性药物代谢产物，从而产生新的抗原性药物-蛋白质加合物，这些新的加合物被宿主的防御系统所针对（半抗原假说），并引发损害肝脏的全身超敏反应（即药物过敏）。
MCE 肝脏毒性化合物库包含 640 种肝脏毒性化合物，是进行肝损伤及相关药物毒理研究的有力工具，该化合物库也可以用来探究 DILI 发病机制，识别早期 DILI 标记物，在药物开发中及时发现并规避可能诱导肝损伤的药物设计，有助于药物的顺利上市。
伴刀豆球蛋白A
Concanavalin A 可与琼脂糖偶联成 Concanavalin A (agarose) (HY-P2149A)。Concanavalin A (ConA) 是一种靶向葡萄糖和甘露糖特异性碳水化合物结构的选择性竞争性结合剂，可诱导有丝分裂，具有一定细胞毒性、肝毒性及致畸性。Concanavalin A 还应用于糖尿病体内血糖监测。
伴刀豆球蛋白A (琼脂糖)
Concanavalin A (agarose) 由与琼脂糖偶联的 Concanavalin A (HY-P2149) 组成。Concanavalin A (ConA) 是一种靶向葡萄糖和甘露糖特异性碳水化合物结构的选择性竞争性结合剂，可诱导有丝分裂，具有一定细胞毒性、肝毒性及致畸性。Concanavalin A (agarose) 可应用于糖尿病体内血糖监测，从复杂样本中“钓出” 特定的糖蛋白或者去除糖杂质。
Vitamin U (S-Methylmethionine sulfonium) chloride是一种具有抗氧化活性的口服抗溃疡剂。Vitamin U chloride 抑制脂肪细胞分化。Vitamin U chloride 可促进皮肤伤口愈合。Vitamin U chloride 可用于胃肠道溃疡的研究。
朝藿定C
Epmedin C (Epimedin-C; Baohuoside-VI) 是一种口服有效的抗炎剂和免疫调节剂，够靶向结合 UCP1、Caspase-1、CDK2 及 Keap1 等多种关键蛋白。Epmedin C 通过破坏 CDK2/Cyclin E 的复合物功能、抑制上皮细胞增殖。Epmedin C 同时上调 Nrf2 表达、降低活性氧水平并抑制促炎因子分泌，从而有效恢复抗体生成并缓解组织损伤。Epmedin C 具有良好的安全性，且无肝毒性或皮肤致敏性，Epmedin C 已用于肥胖症、Deoxynivalenol (HY-N6684) 诱导的免疫毒性以及乳腺增生等疾病研究。
赭曲霉毒素 A
Ochratoxin A 是一种可穿透血脑屏障的食源性真菌毒素，是曲霉属 (Aspergillus) 和青霉属 (Penicillium) 真菌的次生代谢产物，属于 2B 类致癌物。Ochratoxin A 诱导氧化应激、抑制线粒体呼吸、造成氧化性 DNA 损伤、破坏 PPAR-γ-CD36 轴、诱导免疫抑制、介导线粒体依赖性凋亡 (apoptosis)、抑制谷氨酸吸收、引发脱髓鞘病变与神经炎症、导致 DNA 低甲基化及抑制细胞增殖等途径。Ochratoxin A 可诱发肾毒性、肝毒性、免疫毒性、神经毒性，还具有致突变性、致畸性与致癌性。
Icariside I (GH01) 是一种具有口服活性的 Icarlin 代谢产物。Icariside I 通过同时调节成骨细胞和破骨细胞分化改善雌激素缺乏引起的骨质疏松症。Icariside I 促进 ATP (HY-B2176) 或 Nigericin (HY-127019) 诱导的 mtROS 产生以及 NLRP3 炎症小体激活并引起特异质肝毒性。Icariside I 不会改变 NLRC4 和 AIM2 炎性小体的激活。Icariside I 通过靶向 IL-6/STAT3 通路抑制乳腺癌的增殖、凋亡 (apoptosis)、侵袭和转移。Icariside I 是犬尿氨酸-AhR 通路抑制剂，通过阻断肿瘤免疫逃逸来缓解癌症。
Roridin E 是一种葡萄糖-6-磷酸酶 (G6Pase) 抑制剂和抗生素，是 Roridin A (HY-N9599) 的代谢副产物。Roridin E 会引发显著的氧化应激反应，表现为消耗体内谷胱甘肽、诱导肝脏脂质过氧化以及抑制肾脏超氧化物歧化酶活性。Roridin E 能够降低大鼠血糖水平，但具有急性毒性 (与亚油酸 (HY-N0729) 联用时毒性增强)，并会导致雄性白化小鼠出现肝毒性。Roridin E 可诱导血液总蛋白降低以及总脂质、γ-谷氨酰转移酶、碱性磷酸酶和 5'-核苷酸酶水平升高。Roridin E 能够从霉菌中分离得到，具有与 Verrucarin A (HY-107426) 和 Roridin A 相似的细胞抑制和真菌抑制活性。Roridin E 在啮齿类动物中具有体内活性，常被用于肝毒性相关研究。
Sapindoside B 是一种具有保肝活性的物质，同时也是细胞色素 P-450 (cytochrome P-450) 抑制剂、抗菌剂以及膜破坏剂。Sapindoside B 可可逆性抑制肝微粒体细胞色素 P-450 含量，抑制苯巴比妥诱导的酶含量升高，减少细胞色素 P-450 介导的活性代谢产物生成，并减轻肝毒性损伤。Sapindoside B 与 Cutibacterium acnes 脂肪酶结合，降低脂肪酶活性，抑制生物膜形成，减少细菌 (bacterial) 黏附。Sapindoside B 对人癌、肝癌、白血病和胶质母细胞瘤细胞具有细胞毒性。Sapindoside B 可抑制植物病原真菌 (fungal) 的菌丝生长，对皮肤癣菌具有抗菌活性，还具有溶血/溶膜活性。Sapindoside B 可用于肝损伤、Cutibacterium acnes 生物膜相关感染、胃癌、肝癌、早幼粒细胞白血病、胶质母细胞瘤、苹果黑星病以及葡萄灰霉病的相关研究。
Icariside I (Standard) 是 Icariside I (HY-N1939) 的分析标准品。本产品用于研究及分析应用。Icariside I (GH01) 是一种具有口服活性的 Icarlin 代谢产物。Icariside I 通过同时调节成骨细胞和破骨细胞分化改善雌激素缺乏引起的骨质疏松症。Icariside I 促进 ATP (HY-B2176) 或 Nigericin (HY-127019) 诱导的 mtROS 产生以及 NLRP3 炎症小体激活并引起特异质肝毒性。Icariside I 不会改变 NLRC4 和 AIM2 炎性小体的激活。Icariside I 通过靶向 IL-6/STAT3 通路抑制乳腺癌的增殖、凋亡 (apoptosis)、侵袭和转移。Icariside I 是犬尿氨酸-AhR 通路抑制剂，通过阻断肿瘤免疫逃逸来缓解癌症。
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
MedchemExpress Validation 03
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
MedchemExpress Validation 04
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
